Pinnacle Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Pinnacle Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$50K	Buy	+134	New	+$44.7K	﹤0.01%	393

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pinnacle Wealth Advisors's CRL Position: Q2 2021 in Review

Pinnacle Wealth Advisors opened a new position in Charles River Laboratories (CRL) in Q2 2021: 134 shares worth $50K. The stake represents ﹤0.01% of the portfolio and ranks #393 among its holdings.

638 funds tracked by Wall St. Rank hold CRL as of Q2 2021.

Pinnacle Wealth Advisors held 134 shares of Charles River Laboratories worth $50K as of Q2 2021.
Charles River Laboratories was a new Pinnacle Wealth Advisors position in Q2 2021.
Charles River Laboratories made up ﹤0.01% of Pinnacle Wealth Advisors's portfolio in Q2 2021, its #393 holding.
638 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2021.

Based on Pinnacle Wealth Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.